Plus–minus values are means ±SE

Slides:



Advertisements
Similar presentations
Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:
Advertisements

Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Weng TC, et al. J Clin Pharm Ther 2010;35:
B LOOD C HEMISTRY How it affects Cardiovascular Disease.
Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
High Cholesterol High Cholesterol Type of fat Essential nutrient Foods high in saturated fat & cholesterol Liver produces up to 80%
Cardiovascular System Immediate effects Effects of Regular exercise Effects of Lifestyle.
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of the DASH Diet Alone and in Combination.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Application of the Screening for Heart Attack Prevention.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Potential Impact of Time Trend of Life-Style Factors.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2010 American Medical Association. All rights reserved.
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
Copyright © 2009 American Medical Association. All rights reserved.
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
Baseline characteristics and effectiveness results
Activity 4.3.5: Smoking Can Cost You an Arm and a Leg!
Copyright © 2011 American Medical Association. All rights reserved.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Patients Part I
Management of ST-Elevation Myocardial Infarction
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Copyright © 2007 American Medical Association. All rights reserved.
Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where are We Today? H. Bryan Brewer, Jr. Washington Cardiovascular Associates Washington.
Copyright © 2012 American Medical Association. All rights reserved.
Body Mass Index, Sex, and Cardiovascular Disease Risk Factors Among Hispanic/Latino Adults: Hispanic Community Health Study/Study of Latinos by Robert.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Study Design Ketil Lunde, et al. N Engl J Med 2006;355:
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Joshua A. Bell et al. JACC 2018;72:
Updating the science on health assessment
I. Introduction American Journal of Kidney Diseases
Coronary artery bypass grafting in diabetics: A growing health care cost crisis  Sajjad Raza, MD, Joseph F. Sabik, MD, Ponnuthurai Ainkaran, MS, Eugene.
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Subject Characteristics
Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis  Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.
Daan Kromhout, et al. NEJM epub August 29, 2010
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.
Characteristics of the Patients at Baseline*
Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.
Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Subjects*
Study Flow Diagram Thompson A, et al. JAMA 2008;299:
Fig. 6. CXM correlates with age and growth velocity.
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
RECORD Study: Enrollment and Outcomes
Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.
Characteristics of included studies
Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.
Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),
The ACCORD Study Group. NEJM 2010; Epub March 14
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects.
Glycemic control and body weight over 52 weeks.
Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.
Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.
Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.
Presentation transcript:

Baseline Characteristics of the 20 Subjects with Coronary Heart Disease * Plus–minus values are means ±SE. The body-mass index is the weight in kilograms divided by the square of the height in meters. LDL denotes low-density lipoprotein, HDL high-density lipoprotein, and ACE angiotensin-converting enzyme. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for glucose to millimoles per liter, multiply by 0.05551. † ACE inhibitor therapy was withdrawn 7 days before each vascular study. All other regular medications were continued throughout the study. Nicholas L. Mills et al. N Engl J Med 2007;357:1075-82

Effect of Exercise on Heart Rate and ST Segment in the 20 Subjects during Exposures to Filtered Air and Diesel Exhaust* Nicholas L. Mills et al. N Engl J Med 2007;357:1075-82

Myocardial Ischemia during 15-Minute Intervals of Exercise-Induced Stress and Exposure to Diesel Exhaust or Filtered Air in the 20 Subjects Panel A shows the average change in the heart rate and in the ST segment in lead II. Panel B shows the maximum ST-segment depression during inhalation of diesel exhaust as compared with filtered air (P = 0.003), and Panel C shows the total ischemic burden during inhalation of diesel exhaust as compared with filtered air (P<0.001); the values in Panels B and C are averages of the values in leads II, V2, and V5. In all three panels, red indicates exposure to diesel exhaust, and blue exposure to filtered air. T bars denote standard errors, and mVsec millivolt seconds. Nicholas L. Mills et al. N Engl J Med 2007;357:1075-82

Forearm Blood Flow 6 to 8 Hours after Exposures to Diesel Exhaust and Filtered Air Values for infused (solid lines) and noninfused (dashed lines) forearm blood flow are shown for 17 subjects after exposure to diesel exhaust (red) and after exposure to filtered air (blue), as well as for a reference population of matched healthy controls (orange), during intrabrachial infusion of acetylcholine or sodium nitroprusside. P<0.001 for dose response to both drugs in the infused arm. Among the 17 subjects, P = 0.54 for exposure to diesel exhaust versus filtered air during infusion of acetylcholine, and P = 0.56 during infusion of sodium nitroprusside. For the comparison of the subjects with healthy controls, P = 0.02 during acetylcholine infusion, and P = 0.72 during sodium nitroprusside infusion. Nicholas L. Mills et al. N Engl J Med 2007;357:1075-82

Release of Tissue Plasminogen Activator (t-PA) Antigen 6 to 8 Hours after Exposures to Diesel Exhaust and Filtered Air in 17 Subjects As compared with filtered air (blue), inhalation of diesel exhaust (red) reduced the net release of t-PA antigen (calculated as the product of forearm plasma flow and the difference in t-PA concentrations between the two arms) by 35% (P = 0.009). Nicholas L. Mills et al. N Engl J Med 2007;357:1075-82